Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review

Yingshuo HUANG; Wei WEI; Xiaofei TONG; Yameng SUN; Jianxiong ZHANG; Ruihua DONG; Jidong JIA; Hong YOU

doi:10.3969/j.issn.1001-5256.2022.04.012

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 798-804

PDF( 3557 KB)

Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review

DOI: 10.3969/j.issn.1001-5256.2022.04.012

Yingshuo HUANG^a,
Wei WEI^b,
Xiaofei TONG^{c, d, e},
Yameng SUN^{c, d, e},
Jianxiong ZHANG^a,
Ruihua DONG^{a
,
,
,},
Jidong JIA^{c, d, e},
Hong YOU^{c, d, e
,
,
,}

a.
Department of Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
b.
Department of Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
c.
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
d.
Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
e.
National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research funding:

National Natural Science Foundation of China (82130018);

Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXZ03);

Beijing research ward demonstration construction project (BCRW202010)

More Information

Corresponding author: DONG Ruihua, ruihua_dong_rw@163.com(ORCID: 0000-0003-3463-5023); YOU Hong, youhongliver@ccmu.edu.com(ORCID: 0000-0001-9409-1158)
Received Date: 2021-09-07
Accepted Date: 2021-10-15
Published Date: 2022-04-20

Abstract

Abstract

Objective To describe the characteristics and registration status of clinical trials of new drugs for nonalcoholic steatohepatitis (NASH), and to provide a reference for the design and implementation of clinical trials of new drugs for NASH. Methods The U.S. Clinical Trials Database, China Clinical Trial Registry, and Center for Drug Evaluation, National Medical Products Administration, were searched for clinical trials of new drug registration and interventional studies with NASH as the indication published up to August 6, 2021, using NASH in English and Chinese characters as the keywords, and liver cirrhosis was excluded. Two researchers independently searched and screened the articles to extract relevant information. Results A total of 196 clinical trials of new drug registration or interventional studies for NASH were included, among which there were 174 trials registered abroad and 22 trials registered in China, and the number of registrations tended to increase year by year. The numbers of phase Ⅰ, phase Ⅰ/Ⅱ(including Ⅰb/Ⅱa), phase Ⅱ, phase Ⅱ/Ⅲ, and phase Ⅲ clinical trials were 45(23.0%), 8(4.1%), 112(57.1%), 4(2.0%), and 19(9.7%), respectively. The main drug types included farnesoid X receptors, fibroblast growth factors, peroxisome proliferator-activated receptor agonists, and glucagon-like peptide-1, with numbers of 16(8.16%), 14(7.14%), 11(5.61%), and 13(6.63%), respectively. The clinical trials of innovative drugs for NASH initiated by the sponsors in European and American regions accounted for the highest proportion, and there was a gradual increase in the number of clinical trials of innovative drugs in China in recent years, with a similar distribution of single-center and multicenter clinical trials. As for the trials with NASH patients as subjects, the numbers of trials with pathology, imaging, and clinical diagnosis as the main inclusion criteria were 125, 66, and 42, respectively. Phase Ⅰ clinical trials used safety, tolerability, and pharmacokinetic parameters as the main assessment indices, while phase Ⅱ and phase Ⅲ clinical trials often used safety and efficacy as the main assessment indices. The number of clinical trials for the registration of innovative drugs for NASH was relatively low but kept increasing in China, and there were fewer clinical trials of innovative traditional Chinese medicine drugs compared with innovative chemical drugs. Conclusion There is a significant increase in the registration of international clinical trials of innovative drugs for NASH, and most of these trials are in the early phases, with large differences in inclusion criteria and assessment indices, a lack of unified evaluation indices, and relatively few trials with new designs. There are fewer clinical trials of innovative drugs for NASH in China than in European and American countries, and the number of such trials is gradually increasing in China.
- Nonalcoholic Steatohepatitis,
- Clinical Trial,
- Evaluation Studies

FullText(HTML)

References(21)

References

[1]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[2]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[3]	SANYAL AJ, FRIEDMAN SL, MCCULLOUGH AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop[J]. Hepatology, 2015, 61(4): 1392-1405. DOI: 10.1002/hep.27678.
[4]	LAZARIDIS N, TSOCHATZIS E. Current and future treatment options in non-alcoholic steatohepatitis (NASH)[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(4): 357-369. DOI: 10.1080/17474124.2017.1293523.
[5]	ANANIA FA, DIMICK-SANTOS L, MEHTA R, et al. Nonalcoholic steatohepatitis: Current thinking from the division of hepatology and nutrition at the food and drug administration[J]. Hepatology, 2021, 73(5): 2023-2027. DOI: 10.1002/hep.31687.
[6]	RINELLA ME, TACKE F, SANYAL AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD[J]. J Hepatol, 2019, 71(4): 823-833. DOI: 10.1016/j.jhep.2019.04.019.
[7]	China Food and Drug Administration. Guidelines for clinical trials of drugs for the treatment of non alcoholic steatohepatitis[EB/OL]. [2019-12-30]. http://www.nmpa.gov.cn/WS04/CL2138/372284.html. 国家药品食品监督管理总局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则(试行)[EB/OL]. [2019-12-30]. http://www.nmpa.gov.cn/WS04/CL2138/372284.html.
[8]	KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321. DOI: 10.1002/hep.20701.
[9]	KONERMAN MA, JONES JC, HARRISON SA. Pharmacotherapy for NASH: Current and emerging[J]. J Hepatol, 2018, 68(2): 362-375. DOI: 10.1016/j.jhep.2017.10.015.
[10]	REIMER KC, WREE A, RODERBURG C, et al. New drugs for NAFLD: Lessons from basic models to the clinic[J]. Hepatol Int, 2020, 14(1): 8-23. DOI: 10.1007/s12072-019-10001-4.
[11]	TONG XF, SUN YM, YOU H. Evaluation of clinical endpoints in new drug research and development for nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2021, 37(6): 1249-1253. DOI: 10.3969/j.issn.1001-5256.2021.06.003. 佟小非, 孙亚朦, 尤红. 非酒精性脂肪性肝炎新药研发临床终点评价[J]. 临床肝胆病杂志, 2021, 37(6): 1249-1253. DOI: 10.3969/j.issn.1001-5256.2021.06.003.
[12]	DAVISON BA, HARRISON SA, COTTER G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials[J]. J Hepatol, 2020, 73(6): 1322-1332. DOI: 10.1016/j.jhep.2020.06.025.
[13]	CAUSSY C, REEDER SB, SIRLIN CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology, 2018, 68(2): 763-772. DOI: 10.1002/hep.29797.
[14]	JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase Ⅱ trial of selonsertib[J]. J Hepatol, 2019, 70(1): 133-141. DOI: 10.1016/j.jhep.2018.09.024.
[15]	HOOKER JC, HAMILTON G, PARK CC, et al. Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis[J]. Abdom Radiol (NY), 2019, 44(2): 482-492. DOI: 10.1007/s00261-018-1745-3.
[16]	SASSO M, AUDIÈRE S, KEMGANG A, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: A Pilot study assessing diagnostic accuracy[J]. Ultrasound Med Biol, 2016, 42(1): 92-103. DOI: 10.1016/j.ultrasmedbio.2015.08.008.
[17]	VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLA-BERTOT L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149(2): 367-378. e5; quiz e14-e15. DOI: 10.1053/j.gastro.2015.04.005.
[18]	ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4): 829-846. DOI: 10.1016/j.jhep.2017.05.016.
[19]	SANYAL AJ, BRUNT EM, KLEINER DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis[J]. Hepatology, 2011, 54(1): 344-353. DOI: 10.1002/hep.24376.
[20]	RATZIU V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials[J]. J Hepatol, 2018, 68(2): 353-361. DOI: 10.1016/j.jhep.2017.12.001.
[21]	LICHTINGHAGEN R, PIETSCH D, BANTEL H, et al. The enhanced liver fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values[J]. J Hepatol, 2013, 59(2): 236-242. DOI: 10.1016/j.jhep.2013.03.016.

Relative Articles

[1]	Aifang LIU, Lei LUO, Wenlong YANG. Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis[J]. Journal of Clinical Hepatology, 2025, 41(1): 145-150. doi: 10.12449/JCH250122
[2]	Qichao GE, Lungen LU. Value of liver biopsy in the diagnosis and clinical trial of non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(11): 2288-2292. doi: 10.12449/JCH241124
[3]	Center for Drug Evaluation, National Medicine Products Administration. Guidelines for identification, management, and assessment of drug-induced liver injury in clinical trials[J]. Journal of Clinical Hepatology, 2023, 39(8): 1811-1816. doi: 10.3969/j.issn.1001-5256.2023.08.007
[4]	Yu WANG, Xuebing YAN. Advances in phase Ⅲ drug studies on the pipeline in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1398-1401. doi: 10.3969/j.issn.1001-5256.2022.06.037
[5]	Gege TIAN, Enrui XIA, Suyan ZHANG, Shunzhen ZHAGN, Furong XU. Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway[J]. Journal of Clinical Hepatology, 2021, 37(12): 2957-2962. doi: 10.3969/j.issn.1001-5256.2021.12.047
[6]	Huiying RAO, Lai WEI. Interpretation of clinical trial guidelines for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1245-1248. doi: 10.3969/j.issn.1001-5256.2021.06.002
[7]	Xiaofei TONG, Yameng SUN, Hong YOU. Evaluation of clinical endpoints in new drug research and development for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1249-1253. doi: 10.3969/j.issn.1001-5256.2021.06.003
[8]	Yingshuo HUANG, Ruihua DONG, Hong YOU. Difficulties and challenges in the clinical trial of new drugs for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1948-1952. doi: 10.3969/j.issn.1001-5256.2021.08.044
[9]	Ziming AN, Qin FENG. Magnetic resonance imaging-proton density fat fraction: A potential surrogate endpoint for nonalcoholic steatohepatitis clinical trials[J]. Journal of Clinical Hepatology, 2021, 37(6): 1445-1448. doi: 10.3969/j.issn.1001-5256.2021.06.047
[10]	Wang Yu, Rao YouYi, Guo Jun, Yang JianBo, Liu HuaZhu, Zhao XinHua, Pan ShenLiang, Ning Hong. Evaluation and analysis of the current guidelines for acute pancreatitis using Appraisal of Guidelines for Research and Evaluation Ⅱ[J]. Journal of Clinical Hepatology, 2018, 34(6): 1225-1230. doi: 10.3969/j.issn.1001-5256.2018.06.019
[11]	Mao YiMin. Important issues in protocol design of exploratory and confirmatory clinical trials of new drugs for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2509-2514. doi: 10.3969/j.issn.1001-5256.2018.12.005
[12]	Jiang LiNa, Zhao JingMin. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. Journal of Clinical Hepatology, 2018, 34(12): 2505-2508. doi: 10.3969/j.issn.1001-5256.2018.12.004
[13]	Ju HuanJia, Shi JunPing. Clinical trials tracking nonalcoholic fatty liver disease: Noninvasive measures[J]. Journal of Clinical Hepatology, 2018, 34(12): 2501-2504. doi: 10.3969/j.issn.1001-5256.2018.12.003
[14]	Jiang LiNa, Zhao JingMin. Role of histological evaluation of the liver in clinical practice and research on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2303-2306. doi: 10.3969/j.issn.1001-5256.2017.12.009
[15]	Mao YiMin. Clinical trials of investigational new drugs for nonalcoholic steatohepatitis:challenges in design and practice[J]. Journal of Clinical Hepatology, 2017, 33(12): 2292-2295. doi: 10.3969/j.issn.1001-5256.2017.12.007
[16]	Li Qiang, Huang YuXian, Chen Liang. Current studies of novel drugs against hepatitis B virus in clinical trials[J]. Journal of Clinical Hepatology, 2016, 32(2): 370-373. doi: 10.3969/j.issn.1001-5256.2016.02.038
[17]	Ji Guang. Relevant issues concerning clinical trials of traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(4): 299-302. doi: 10.3969/j.issn.1001-5256.2014.04.003
[18]	Xu Hui, Wen QinSheng, Wang XuXia, Zhang YaFei, Li Jun, Gu BingQuan. The effect of cimetidine on the blood sugar, serum insulin and other indexes in NASH rats[J]. Journal of Clinical Hepatology, 2007, 23(2): 112-114.
[20]	Dai Lin, Deng Bin, Li AiPing, Yu HongBo, Bai Cheng, Lu ShengMing. Experimental study on the pathogenesis of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2004, 20(5): 285-286.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	王佳丹，郑叶，彭秀华，张健，陈晓蓉，刘荣. 软肝逐瘀方对高脂饮食诱导的小鼠非酒精性脂肪性肝炎的疗效评价. 世界临床药物. 2024(05): 470-477 .
2.	汪云，崔桅. 非酒精性脂肪性肝炎在研新药的现状及进展. 中国处方药. 2023(08): 190-193 .
3.	刘玉嫣，朱邗枝，贾步云，陈光亮. 治疗非酒精性脂肪性肝炎药物研究进展. 中国新药杂志. 2023(20): 2044-2050 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(6)

Get Citation

PDF

XML

Article Metrics

Article views (1093) PDF downloads(166)

Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review

DOI: 10.3969/j.issn.1001-5256.2022.04.012